Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential
participant.
The goal of this clinical research study is to find the highest tolerable dose of the
combination of temsirolimus and metformin that can be given to patients with advanced cancer.
The safety of the drug combination will also be studied.
Temsirolimus is designed to block a protein called mTOR (a protein that is thought to cause
cancer cells to grow) inside the cancer cell. This may interfere with the growth or spread of
cancer cells or possibly kill them.
Metformin was designed to treat patients with diabetes. It may be able to block the protein
mTOR and slow the growth of tumors.
This is an investigational study. Temsirolimus is FDA approved and commercially available for
the treatment of renal cell carcinoma. Metformin is FDA approved and commercially available
for the treatment of diabetes mellitus. The combination of these drugs to treat advanced
cancer is investigational.
Up to 104 patients will take part in this study. All will be enrolled at MD Anderson.